Uncategorized

Uncategorized

New Releases from NCBI BookshelfNTP Technical Report on the Toxicology and Carcinogenesis Studies of α-Pinene (CASRN 80-56-8) Administered by Inhalation to Sprague Dawley (Hsd:Sprague Dawley® SD®) Rats, B6C3F1/N Mice, and CD-1 Mice: Technical Report 606 [Internet].​NTP Technical Report on the Toxicology and Carcinogenesis Studies of α-Pinene (CASRN 80-56-8) Administered by Inhalation to Sprague Dawley (Hsd:Sprague Dawley® SD®) Rats, B6C3F1/N Mice, and CD-1 Mice: Technical Report 606 [Internet].

α-Pinene is a naturally occurring monoterpene produced by some plants (e.g., pine trees, cannabis, rosemary) and is used as a […]

Uncategorized

New Releases from NCBI BookshelfLebrikizumab (Ebglyss): Indication: For the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years of age and older with a body weight of at least 40 kg, whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. Lebrikizumab can be used with or without topical corticosteroids: Reimbursement Recommendation [Internet].​Lebrikizumab (Ebglyss): Indication: For the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years of age and older with a body weight of at least 40 kg, whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. Lebrikizumab can be used with or without topical corticosteroids: Reimbursement Recommendation [Internet].

Canada’s Drug Agency (CDA-AMC) recommends that Ebglyss be reimbursed by public drug plans for the “treatment of moderate-to-severe atopic dermatitis

Uncategorized

New Releases from NCBI BookshelfTezepelumab (Tezspire): Indication: As an add-on maintenance treatment with intranasal corticosteroids in adult patients with severe chronic rhinosinusitis with nasal polyps (CRSwNP) inadequately controlled by systemic corticosteroids and/or surgery: Reimbursement Recommendation [Internet].​Tezepelumab (Tezspire): Indication: As an add-on maintenance treatment with intranasal corticosteroids in adult patients with severe chronic rhinosinusitis with nasal polyps (CRSwNP) inadequately controlled by systemic corticosteroids and/or surgery: Reimbursement Recommendation [Internet].

Canada’s Drug Agency (CDA-AMC) recommends that Tezspire be reimbursed by public drug plans as an add-on maintenance treatment with intranasal

Scroll to Top